Hagen T C, Lawrence A M, Kirsteins L
Horm Metab Res. 1978 Jul;10(4):310-3. doi: 10.1055/s-0028-1093421.
The in vitro growth hormone releasing activity of plasma obtained from six acromegalic subjects was measured before and during therapy. In five subjects, plasmas were obtained before and during successful medical therapy with medroxyprogesterone acetate (MPA). The sixth subject was sampled before and after transphenoidal Sr90-induced hypopituitarism. All subjects had a decrement in fasting growth hormone levels with respective therapies (29-88%). The in vitro growth hormone released from Rhesus monkey anterior pituitaries was assessed after incubating one lateral half in control plasma (pre-therapy) and the contralateral pituitary half in plasma obtained during or after therapy. Studies with plasmas obtained from the five patients successfully treated with MPA showed a decreased in growth hormone releasing activity during therapy in all (18-57%). Plasma obtained after Sr90 pituitary ablation in the sixth subject had 35% more growth hormone releasing activity than obtained before therapy. These results suggest that active acromegalics who respond to MPA with significantly lowered growth hormone levels may actually achieve this response because of a decrease in growth hormone releasing factor measured peripherally. The opposite response in one acromegalic subject, following Sr90 pituitary ablation and hypopituitarism, suggests that growth hormone releasing factor secretion may increase when growth hormone levels are lowered by ablative therapy.
在治疗前及治疗期间，对6名肢端肥大症患者的血浆进行了体外生长激素释放活性测定。其中5名患者在使用醋酸甲羟孕酮（MPA）进行成功药物治疗前及治疗期间采集了血浆。第6名患者在经蝶窦Sr90诱导垂体功能减退前后进行了采样。所有患者在各自治疗后空腹生长激素水平均有下降（29% - 88%）。将恒河猴垂体前叶的一侧半片在对照血浆（治疗前）中孵育，另一侧半片在治疗期间或治疗后采集的血浆中孵育，之后评估体外释放的生长激素。对5名成功接受MPA治疗的患者的血浆研究表明，治疗期间所有患者的生长激素释放活性均下降（18% - 57%）。第6名患者在Sr90垂体切除术后采集的血浆，其生长激素释放活性比治疗前高35%。这些结果表明，对MPA有反应且生长激素水平显著降低的活跃型肢端肥大症患者，其实际获得这种反应可能是由于外周测量的生长激素释放因子减少。一名肢端肥大症患者在Sr90垂体切除术后垂体功能减退出现相反反应，这表明当通过切除疗法降低生长激素水平时，生长激素释放因子的分泌可能会增加。
